Optical coherence tomography (OCT) is a well-established technique for the clinical examination, diagnosis, severity staging and monitoring of ophthalmic disorders. The application of this technology has more recently been extended beyond ophthalmic disease, whereby it has been demonstrated that OCT can serve as an ophthalmic marker for a range of systemic neurodegenerative disorders, such as Parkinson's disease, multiple sclerosis, Alzheimer's disease and diabetic peripheral neuropathy. This review will focus on the clinical utility of OCT-derived retinal measures for the investigation of these conditions.
patients may also experience visual symptoms such as decreased visual acuity, difficulty reading, double vision and poor hand-eye co-ordination. 2, 3 Some age-related neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease can cause visual hallucinations, colour vision deficits and scotomatous areas in the visual field, 3 that present several challenges in performing everyday tasks. With the increase in population age, these disorders have become more prevalent. Therefore, clinical techniques are required to detect these changes at an earlier stage and to predict future onset of disease. The eye makes an ideal site for a more direct and a non-invasive examination of neurological disorders. One such examination technique is optical coherence tomography (OCT), introduced by Huang et al. 4 in 1991.
OCT has revolutionised clinical assessment, follow-up and management of ophthalmic pathologies. It is an efficient technique for the objective evaluation of retinal structural integrity. OCT provides an in vivo histological view, similar to optical biopsy of the ocular tissues, and has sufficiently high resolution to allow individual layers to be distinguished. OCT is a non-contact, non-invasive technique that is quick to perform.
Two-dimensional tomography is based on the time delay and intensity of light that is backscattered from the ocular tissues under examination. It utilises low coherence interferometry similar to ultrasound, but uses infrared light to image individual tissue layers. Huang et al. 4 at the Massachusetts Institute of Technology developed the first two-dimensional B-scan, wherein A-scans were obtained by changing the position of the mirror. The prototype was further developed into a commercial instrument with an axial resolution of 15 μm and a scanning rate of 25,000 to 40,000 A-scans per second. Recent developments in OCT technology can produce up to 100,000 A-scans per second, with a higher resolution and greater penetration depth when compared to most currently available commercial instruments. OCT utilises high and low contrast properties of living tissues to differentiate various layers. 5 In ophthalmic tissue, the sclera (imaged with an anterior segment OCT) and blood vessels are often imaged as highcontrast structures relative to other tissues. The retina, being highly vascularised and innervated, makes an ideal site for imaging, as neuronal, vascular and support structures vary in contrast. Changes in the retina as imaged with posterior segment OCT have been investigated as potential 'markers' for systemic and ophthalmic vascular and neurological disorders such as Alzheimer's disease and Parkinson's disease, and as end-points in clinical trials for the treatment of optic neuritis and multiple sclerosis. In this context, the OCT could serve as a first line of screening for the non-invasive detection of systemic neurodegenerative disorders.
Of the neuroretinal structures that can be imaged using OCT, the retinal nerve fibre layer and the ganglion cell complex have received great attention in recent years. Figure 1 is a schematic diagram showing the specific retinal zones that are imaged when assessing the retinal nerve fibre layer and ganglion cell complex. The ganglion cell complex essentially comprises three layers: the nerve fibre layer, made up of axons of ganglion cells; the ganglion cell layer, made up of cell bodies of ganglion cells; and the inner plexiform layer, made up of dendrites of ganglion cells. The retinal nerve fibre layer represents axons of the ganglion cells. Changes to these two specific retinal structural components have been correlated with changes in visual fields, and are being investigated as potential markers for early-stage disease. Macular thickness has also been investigated in this regard ( Figure 2 ).
This review presents an overview of theAlzheimer's disease and diabetic peripheral neuropathy.
Parkinson's disease
Parkinson's disease is a progressive neurodegenerative disorder characterised by loss of nerve cells in the substantia nigra of the brain and accumulation of Lewy bodies (abnormal aggregates of the protein, α-synuclein). 6 This in turn results in loss of dopaminergic cells followed by a reduction in the neurotransmitter, dopamine. Dopamine regulates body movement, and therefore, a reduction in dopamine is characterised by involuntary shaking of the body, stiffness of skeletal muscles and loss of balance. The aetiology of Parkinson's disease has been proposed to be a combination of genetic and environmental factors. Men are more likely to be affected by this disorder. Neuronal cell death and dysfunction is evident in the central nervous system. In postmortem eyes, fewer dopaminergic neurons have been demonstrated in the retina of those with Parkinson's disease compared to those without the disease. 7, 8 This was later confirmed by the observation of reduced circuitry (comprising of receptors, horizontal cells and bipolar cells) in the retina. 9 At the outset, the retinal nerve fibre layer thickness, 10, 11 particularly the inferior quadrant, 12 has been found to be significantly reduced in patients with Parkinson's disease compared with healthy agematched controls.
In rodents, a rotenone-induced Parkinson's disease model has been utilised for an improved understanding of the disease. Rotenone is a pesticide used by farmers, but is found to exert neurotoxic effects that produce characteristics that closely resemble clinical features of Parkinson's disease. Rotenone used in vivo or in vitro, when administered by subcutaneous, intravenous or intraperitoneal routes, causes selective inhibition of mitochondrial complex 1, increased oxidative stress, and release of free radicals. There is also a decrease in adenosine triphosphate synthesis, leading to selective degeneration of the nigrostriatal dopamine system, which produces features of clinical Parkinson's disease.
An OCT study in rotenone-induced rodent models revealed retinal ganglion cell death and a temporary swelling of the retina after 20 days of rotenone insult; however, loss of dopaminergic cells was evident in the substantia nigra only after two months, suggesting that retinal changes may precede cell loss in the brain. 6 In humans, Hajee et al. 13 14 Not only is retinal nerve fibre layer thickness compromised in the superior, nasal and inferior quadrants in patients with Parkinson's disease, total macular thickness and volume [15] [16] [17] is also significantly reduced. A thinner inner plexiform layer, outer nuclear layer, photoreceptor layer and retinal pigment epithelium layer 18 may contribute to reduced thickness in the overall macular region. In contrast, the outer plexiform layer thickness 18 and volumes 19, 20 are noted to be higher in Parkinson's disease. The greater thickness of the outer plexiform layer has been proposed to be due to aggregation of α-synuclein in the outer plexiform layer in patients with Parkinson's disease. The protein α-synuclein is found in plenty in the synaptic terminals in the brain and in small quantities in other tissues such as heart and muscle. An abnormal deposition of α-synuclein (called Lewy bodies) -not only in the brain but also in retinal layersis observed in Parkinson's disease. Shallowing, 21 widening, 18 and thinning 22 of the foveal pit also has been observed with increasing severity of Parkinson's disease. Thus, OCT proves to be a promising tool in identifying neuronal degeneration from an in-depth analysis of individual retinal layers.
As for the choroid, peripapillary choroidal thickness 10, 23 is reported to be higher in Parkinson's disease, but decreases with increasing distance from the optic nerve head. It has been proposed that greater choroidal thickness may be related to changes in the density of connective tissue surrounding vessels in patients with Parkinson's disease. 23 The compromise in retinal structure described above is reported to be associated with various types of visual dysfunction, such as altered colour vision, reduced contrast sensitivity 24 and central visual field loss. 25 Retinal structural changes are reported to be associated with delayed implicit times and decreased amplitudes of multifocal electroretinogram in patients with Parkinson's disease compared to the control subjects, suggesting that the photopic response/function is compromised. Retinal thickness and volume measures, combined with amplitude and implicit time from the multifocal electroretinogram, are reported to have a higher diagnostic capability than individual measures. 26 A positive correlation has been reported between contrast sensitivity and inner and total macular thicknesses. 15, 27 The diagnostic capability of OCT, assessed as the areas under the receiver operating characteristic curve, in diagnosing patients with Parkinson's disease has been reported to be 0.784 for both parafoveal thickness and contrast sensitivity scores. This measure increases to 0.844 with the addition of N70 and P100 latencies of visually evoked potentials. 27 Garcia-Martin et al. 28 performed a com- 30 included patients with early Parkinson's disease, who were followed up closely with a minimum of six-monthly visits. It is likely that the early stage of disease precluded many ophthalmic parameters from demonstrating a decline at follow-up. It should also be noted that the presence of tremors can present a significant challenge, and be uncomfortable, for a patient with Parkinson's disease to undergo OCT, visual fields and electrodiagnostic testing. Nevertheless, both studies are significant in that they emphasise the importance of screening during early stages of the disease and the requirement for close follow-up.
OCT measures have been found to be correlated with cognitive function. For instance, a positive correlation has been reported between cognitive function assessed by mini-mental state examination and retinal nerve fibre layer thickness. 11 Similarly, retinal nerve fibre layer thickness and foveal thickness were lower in patients who had a lower quality of life score and more severe symptoms of Parkinson's disease. The N95 component of the pattern electroretinogram has been indicated to be a reliable marker for predicting the quality of life and disease severity. It appears that several retinal layers and the choroid are affected in patients with Parkinson's disease, in both early and late stages of the disease. When a patient presents to a neurology or eye clinic, and mild tremors are noted, OCT may be utilised as a screening test. If retinal structural compromise is detected, then there is likelihood that the patient has Parkinson's disease.
In some patients, it is likely that OCT may be essentially normal. However, testing of functional measures such as colour vision, contrast sensitivity, and multifocal or pattern electroretinogram, may reveal visual functional compromise, which may have a better diagnostic capability than individual measures. Although colour vision and contrast sensitivity can be confounded by age and/or age-related cataract, a multifocal or pattern electroretinogram can surpass these limitations and provide a more definitive assessment of functional compromise. Such ophthalmic measures may be used to assess the patient at regular intervals for follow-up and to assess the progression of the disease.
Eye care practitioners such as optometrists could play a role in the detection of retinal structural compromise at an early stage, leading to an appropriate and timely referral. Although at present there is no cure for Parkinson's disease, retinal assessment by OCT can possibly detect early stages of the disease even before the appearance of obvious symptoms, and can serve as a prompt to initiate treatment (such as levadopa) for symptoms of tremor. Symptomatic treatment for tremors can make a positive significant difference to the daily activities of patients with Parkinson's disease, especially if there are co-existing ophthalmic disturbances such as visual field or colour vision defects.
Multiple sclerosis
Multiple sclerosis is a demyelinating disorder that affects the central nervous system. Unknown infections and some environmental factors have been reported to initiate an autoimmune response to self-antigens that works against the myelin, cellular and axonal components. The optic nerve (second cranial nerve), is a part of the central nervous system that has oligodendrocytederived glial cells between its nerve fibres. The oligodendrocytes are the main source of myelin production. 31 Inside the eye, the nerve fibres are unmyelinated, but once the fibres exit the eye, they acquire a myelin sheath. In multiple sclerosis, the myelin and axons are affected. The irreversibility of axonal loss poses a threat to retinal structure and function. Therefore, imaging the retina and optic nerve in multiple sclerosis has significant potential diagnostic utility. The disease can involve multiple systems and can lead to blurred vision, loss of balance, muscle stiffness, fatigue, and problems with coordination of the legs or arms.
Several studies have reported the utility of OCT in the assessment of patients with multiple sclerosis. The Optic Neuritis Treatment Trial reports that optic neuritis is a frequent ophthalmic complication of multiple sclerosis, occurring as the first finding in about 20 per cent of patients with the disease, and in about 70 per cent of patients any time after onset.
In the presence of acute optic nerve oedema in anterior optic neuritis, the retinal nerve fibre layer is documented as being thicker when assessed at regular intervals over six months.
Following the first event of optic neuritis, there is axonal loss and nerve fibre layer thinning. Axonal loss is then said to reach a plateau. [32] [33] [34] Increased retinal nerve fibre thickness measured during the initial few weeks after diagnosis has been hypothesised as being due to retinal nerve fibre layer oedema, 33 as a result of acute injury.
However, retinal nerve fibre layer thinning assessed three to six months after optic neuritis is suggestive of axonal injury. The optic nerve head also becomes pale over time, which corroborates with the retinal nerve fibre layer loss. The magnitude of this damage has been reported to be 20-25 per cent when compared to the fellow unaffected eye. 32, 34, 35 Retinal nerve fibre layer loss is usually generalised, affecting all quadrants, but has a predilection toward the temporal quadrant, 36 suggesting that the papillomacular bundle is most affected. Measurement of retinal nerve fibre layer thickness has been shown to provide an objective assessment of axonal and neuronal degeneration in patients with multiple sclerosis, even in the absence of optic neuritis 37 due to lesions beyond the optic nerve head. For instance, in the normal eye, OCT demonstrated axonal loss in the presence of normal visual acuity and visual fields, suggesting subclinical changes, while the fellow eye with optic neuritis showed retinal nerve fibre layer thinning. 34 One study examined retinal nerve fibre layer and ganglion cell-inner plexiform layer thickness in patients with intracranial lesions affecting the optic chiasm and in another set of patients with optic tract and/or lateral geniculate nucleus involvement. About 76 per cent of patients in the first group showed both nasal and temporal ganglion cell-inner plexiform layer thinning. All patients in the second group showed thinning of both nasal and temporal ganglion cell-inner plexiform layers, but only half the number of patients showed retinal nerve fibre layer thinning, 38 ,39 It appears that post-chiasmal lesions affect the nerve fibre layer as well as the ganglion cell-inner plexiform layer, while pre-chiasmal lesions closer to the eye affect predominantly ganglion cell complex-inner plexiform layer thicknesses. Nevertheless, both retinal nerve fibre layer and ganglion cell-inner plexiform layer thicknesses are valuable measures for assessing abnormalities in the visual pathway. Thinning of the retinal nerve fibre layer may be a squealae to transneuronal degeneration because of the lesions in the optic radiations and/or beyond. 40 Although the exact mechanism for this neuroaxonal degeneration is not known, it has been hypothesised that there could be: (i) retrograde degeneration in the presence of mild subclinical optic neuritis; (ii) primary degeneration of ganglion cell complex and retinal nerve fibre layers due to multiple sclerosis; and (iii) degeneration due to lesions in the optic radiation via transsynaptic degeneration. 41 Retinal nerve fibre layer measures in multiple sclerosis have been found to be correlated with visual functional and cognitive measures. For instance, axonal loss documented with OCT correlates with functional changes measured using electrophysiological techniques. Therefore, assessment of the retinal nerve fibre layer provides a gateway to understanding the anterior neural pathway 42 of this neurodegenerative process occurring in the brain and spinal cord. Decreased temporal retinal nerve fibre layer thickness is associated with physical and cognitive disability and impaired visual function. In patients with visual dysfunction, a retinal nerve fibre layer thickness of 75 μm is said to be a cut-off value below which there is permanent visual dysfunction; a 10 μm decrease in retinal nerve fibre layer thickness predicted a 6.83 dB decrease in the mean deviation of the visual field plot. 33 However, OCT is capable of detecting axonal loss in about two-thirds of patients with essentially normal visual field, 34 thus making it a valuable tool for detecting subclinical neuroretinal degeneration in patients with multiple sclerosis.
Retinal nerve fibre layer thickness has been assessed as an end-point in a few clinical trials of multiple sclerosis. In the Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis trial, 43 optic nerve conduction latency improved after administration of opicinumab in patients who had their first episode of optic neuritis; however, neither retinal nerve fibre layer thickness nor visual function showed any improvement. It is therefore critical to follow-up patients suffering from multiple sclerosis on a regular basis to monitor neuroretinal loss, because retinal nerve fibre layer thinning is irreversible. A decrease in macular volume has been noted in patients with multiple sclerosis, 44 more so in the nasal portions, 45 which may corroborate with compromised retinal nerve fibre layer thickness in the temporal quadrant as reported in a previous study. 36 Evangelou et al. 46 examined the size distribution of neurons in the magnocellular and parvocellular layers of the lateral geniculate body, and axonal densities of the anterior visual pathway. They observed that the distribution of neuron size in the lateral geniculate body was correlated with axonal densities in the visual pathway. In addition, they observed there were no significant differences in neuronal size distribution between patients and controls in magnocellular layers. In parvocellular layers, cell sizes were smaller in those with multiple sclerosis compared with those of healthy controls, suggesting that smaller axons may be susceptible to damage from multiple sclerosis. 46 Since many diseases have vascular abnormalities, imaging and quantifying retinal and choroidal blood flow has captured the attention of vision scientists. While conventional OCT generates cross-sectional images from backscattered light, it cannot be used to monitor vascular changes because of the low contrast between capillaries and retinal tissue. A more recent development in OCT technology is OCT-angiography -a new imaging tool which allows for a non-invasive visualisation of the microvasculature such as capillary networks of the retina and choroid. This technique largely obviates the need for fluorescein angiography. 47 The change in OCT reflectance signal brought about by moving red blood cells in repeated scans is utilised in identifying blood vessels and is quantified. This creates a three-dimensional blood flow map 40 
-hand co-ordination). If this is normal, a pupillary examination may reveal a relative afferent pupillary defect or abnormal pupillary reactions to light, and can be followed by examination of the optic nerve head. The optic nerve head may appear normal in case of lesions beyond the optic nerve head. In this case, an OCT examination can be combined with visual field or colour vision tests, which may reveal retinal structural or functional compromise, or both, even in the absence of clinically visible optic neuropathy. The individual may then be referred to a neurologist for further investigation to confirm the diagnosis and to consider the early use of neuroprotective drugs, so as to prevent further axonal loss.
Alzheimer's disease
Alzheimer's disease is a common neurodegenerative disorder associated with memory loss and cognitive impairment. 50 Structural manifestations in the brain include deposition of amyloid plaques, hippocampal atrophy, and neurofibrillary tangles in the hippocampus, amygdala and basal nucleus of Meynert. 50 It has been reported that there is a gradual transition towards Alzheimer's disease, in which the amyloid plaque deposition occurs prior to the onset of impairment in cognitive function, while neurofibrillary tangles, neuron loss, and particularly synaptic loss, occur in parallel to the progression of cognitive decline. The changes described above are detectable only through cerebrospinal analysis, imaging or post-mortem examination of brain tissue. 51 Nevertheless, the similarity in embryological origin of the brain and eye makes it possible to examine the eye for any neurological complications. 52 Some of the ophthalmic manifestations of Alzheimer's disease include decrease in visual acuity, visual field defects and decreased colour vision, which is associated with reduced macular volume. OCT examination reveals a thinner retinal nerve fibre layer in patients with Alzheimer's disease. [53] [54] [55] [56] [57] [58] Retinal nerve fibre layer thickness is reported to be lower 59, 60 overall as well as in all four quadrants in comparison to that of healthy controls. In a systematic review and meta-analysis, Thomson et al. 61 found retinal nerve fibre layer thickness to be lower in patients with Alzheimer's disease by an average of 12 μm. Retinal nerve fibre layer thickness was found to be reduced by 25 μm in the superior, 16 μm in the inferior, 8 μm in the temporal and 9 μm in the nasal quadrants, in those with Alzheimer's disease, compared with matched controls. The retinal ganglionic cell complex has also been documented to be thinner in patients with Alzheimer's disease. For instance, significantly lower overall, superior and inferior ganglion cell complex thicknesses have been observed in patients with Alzheimer's disease compared with healthy controls, which correlate with the severity of the disease. [62] [63] [64] These changes have been hypothesised to occur because of retrograde degeneration of ganglion cells.
Another hypothesis is that atrophy may occur as a result of deposition of amyloid-B plaques in the retinal layers. In some patients, deposition of amyloid plaques in the retina occurs prior to cognitive decline, 50 which makes OCT a promising tool for detecting Alzheimer's disease in its early stages. A thinner retinal nerve fibre layer and/or ganglion cell complex may affect peripheral and central visual fields, respectively. This may present mobility issues which can exacerbate the pre-existing disability.
Because about one-third of neurons emanating from the macular area converge at the optic nerve head, attention has been directed toward examination of macular thickness. It has been observed that retinal thickness in all quadrants of the macula is significantly lower when compared to that of healthy controls, especially in the inferior, temporal and nasal quadrants. 65 In addition, macular volume has been found to be lower in patients with Alzheimer's disease. 66 A thinner macula may be a reflection of a thinner ganglion cell layer, loss of glial cells and/or loss of blood vessels. Salobrar-Garcia et al. 67 reported significantly thinner macular parameters in patients with milder forms of Alzheimer's disease in the presence of nonsignificant thinning of the peripapillary retinal nerve fibre layer when compared to that of age-matched controls. This is possibly because the ganglion cells are multilayered at the macula and therefore thinning may be relatively easier to detect. Alzheimer's disease may exhibit a differential influence on retinal nerve fibre layer versus macular parameters, which may be useful in assessing the severity of the disease. This finding suggests that macular thickness may serve as an additional 'marker' in the diagnosis of milder forms of Alzheimer's disease. Mild cognitive impairment is considered to be an intermediate stage of Alzheimer's disease; that is, somewhere between a healthy normal state and a confirmed diagnosis of Alzheimer's disease. This condition is characterised by loss of memory that interferes with everyday routine. 68 The memory loss is abnormal when compared to an age-related healthy cohort, but not as high as in established Alzheimer's disease. 69 Few studies have assessed retinal nerve fibre layer thickness in patients with mild cognitive impairment. One study 70 observed that the overall retinal nerve fibre layer thickness was about 14 μm lower in those with mild cognitive impairment compared with healthy controls. Kesler et al. 71 studied patients with mild cognitive impairment and those with Alzheimer's disease and found that the retinal nerve fibre layer is significantly thinner, especially in the inferior quadrant, in both groups (compared to controls), but the superior retinal nerve fibre layer was significantly thinner only in the Alzheimer's group. This suggests that there are differences in the extent of retinal nerve fibre layer involvement between mild cognitive impairment and Alzheimer's disease. In contrast, others have reported that macular thickness and volume is higher in patients with mild cognitive impairment. 72, 73 Higher macular thickness has been proposed to be related to inflammation/gliosis 74 occurring during early stages of Alzheimer's disease, preceding neuronal loss in the brain.
Reduced retinal nerve fibre layer thickness measured with OCT, without any obvious clinically visible retinal findings, may raise the suspicion of glaucoma. However, Alzheimer's disease is characterised by memory loss in early stages and cognitive impairment in late stages, which is not necessarily observed even in elderly patients with glaucoma. This is because memory loss in Alzheimer's disease or mild cognitive impairment is much higher than that due to the normal ageing process. In addition, some of the ophthalmic measures correlate with measures of cognitive function (discussed later) and are reported to occur in parallel with the progression of cognitive decline, which is another sign not observed in glaucoma.
Using OCT-angiography, it has been demonstrated that in certain diseases that affect the eye, the superficial and deep plexus can be differentially affected. For instance, in patients with Alzheimer's disease, the densities of superficial and deep retinal vascular networks are less than normal, with a decreasing trend from controls to mild cognitive impairment to Alzheimer's disease. In those with mild cognitive impairment, only the density of the superior deep vascular plexus is decreased. This suggests a compromise, possibly at the level of the ganglion cell layers, 75 which supports the argument that loss of ganglion cells, because of compromised vascular networks, may contribute to a thinner macula. OCT-angiography is superior to fluorescein angiography in that it is non-invasive, with no side effects, and provides detailed information about the superficial, deep and the middle capillary plexus.
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Alzheimer's disease is associated with lower retinal vascular density, an enlarged foveal avascular zone and a lower choroidal thickness, compared with age-matched controls. 77, 78 The enlargement of the foveal avascular zone has been proposed to be due to micro-infarction in the neighbouring arcades. 79 The choroid is a highly vascularised structure which supplies oxygen to the outer retina. The foveal avascular zone derives its blood supply from the choroid. Any disruption to the choroidal vasculature may affect visual function, such as reduced visual acuity at low levels of illumination, lower reading speed, reduced contrast sensitivity or poor colour discrimination. The pathogenesis behind choroidal thinning has been proposed to be deposition of amyloid in choroidal vessels, followed by atrophy of the choroid. 78 Such losses in visual function would represent a significant disability for individuals with this disorder and may compromise quality of life. In addition to the above findings, studies have demonstrated a link between OCT measures and psychological tests, such as the mini-mental state examination, that are utilised to assess cognitive function. 65, 72, 80, 81 The retinal nerve fibre layer and macular parameters have been shown to be correlated with mini-mental state examination scores. Furthermore, vascular density parameters, choroidal thickness and the foveal avascular zone have been found to correlate with mini-mental state examination scores. 77 OCT has been used to examine the effects of treatment on retinal nerve fibre layer degeneration. Interestingly, treatment has been shown to protect the existing retinal nerve fibre layer from further damage in multiple sclerosis. 8, 82 Herrero et al. 83 followed up treated and untreated patients for three years, and observed that the retinal nerve fibre layer undergoes gradual thinning over a three-year follow-up, with the loss being greater in untreated patients. The extent of retinal nerve fibre loss was found to be commensurate with the slow disease progression in multiple sclerosis. This study demonstrates an additional yet an interesting role of OCT in the assessment of treatment outcomes and the potential to serve as a surrogate measure of disease progression. Since the deposition of amyloid plaques in the retina occurs prior to cognitive decline, 50 OCT is a promising tool for detecting Alzheimer's disease in its early stages. Reduced retinal nerve fibre layer and ganglion cell complex thicknesses, but a higher macula thickness, may represent inflammation or gliosis, and may be pathognomonic of early-stage Alzheimer's disease patients with abnormal memory loss. Symptoms of memory loss or cognitive decline combined with visual symptoms can jeopardise quality of life and therefore, necessitates early investigation in order to initiate appropriate treatment. In this regard, OCT appears to be a valuable tool for the early detection, assessment and follow-up of patients with Alzheimer's disease or mild cognitive impairment, and in monitoring response to treatment.
Diabetic peripheral neuropathy
Diabetic peripheral neuropathy (DPN) is a devastating complication affecting 40-50 per cent of individuals with diabetes. The peripheral nerves in the distal feet are affected insidiously in diabetes, 84 of sensation. Foot ulceration is a frequent complication in those with diabetes who have suffered a significant loss of sensation in the lower limbs, and consequently do not feel any pain or discomfort in the presence of lower limb pathology. Foot ulceration can occur irrespective of foot trauma. This can eventually lead to amputation as a consequence of poor wound healing in diabetes.
In fact, the presence of symptoms is said to be an advantage whereby those affected become aware of the problem and seek attention.
Traditional investigations for DPN include vibration threshold tests or electrophysiology, which predominantly explore the function of large nerve fibres. However, small nerve fibres seem to be affected much before large nerve fibres. Small nerve fibre function tests include assessment of temperature, pinprick and pain sensations. However, these tests are subjective and the results are highly variable. Skin/nerve biopsy in the leg can accurately and objectively assess the damage caused by DPN; however, such tests are invasive and uncomfortable. These deficiencies have led to the investigation of objective, non-invasive markers that better define DPN. 85 The retina is highly vascularised and richly supplied by nerves and is therefore an ideal site for an in vivo examination of neural tissue. The authors' previous pilot study examined the retinal nerve fibre layer in individuals with and without neuropathy. It was observed that retinal nerve fibre thickness is compromised in relation to the severity of diabetic neuropathy 86 when adjusted for age, duration of diabetes and diabetic retinopathy. This suggests that retinal neuronal degeneration, that has been thought to be a precursor to diabetic retinopathy, may correlate with neurodegenerative changes in distal peripheral nerves, such as in the feet, in individuals with diabetes, and is not related to diabetic retinopathy. It may represent early signs of retinal nerve fibre damage in the eye in the absence of clinical signs of diabetic retinopathy. A comprehensive approach was taken to study macular thickness, peripapillary retinal nerve fibre thickness and ganglion cell complex thickness, in individuals with diabetes and neuropathy. It was observed that DPN has an influence on macular integrity. 87 For example, the perifovea, which represents the outer macular zone, is compromised in relation to DPN, when adjusted for age, sex, refractive error, duration of diabetes and glycated haemoglobin (HbA 1c ) levels. In addition to this, the retinal nerve fibre layer is compromised in relation to DPN. It was interesting to note that the ganglion cell complex thickness showed an inverse relationship to DPN but the association did not reach statistical significance. These findings may suggest that the retinal nerve fibre layer, which essentially represents the axons of the ganglion cells, may be affected before the ganglion cells.
To better understand the disease process, ganglion cell complex pattern-based parameters 88 were further investigated -namely, focal loss volume and global loss volume, and the proportion of those with abnormal loss in ganglion cell complex volume, in patients with diabetes in relation to both diabetic retinopathy and DPN. The focal loss volume represents the loss in ganglion cells at each pixel in comparison to the agerelated normative database and is analogous to the pattern standard deviation of visual fields. The global loss volume represents a generalised loss in ganglion cell complex volume over the entire ganglion cell complex map and is analogous to the mean deviation of visual fields. 89 Abnormal focal or global loss in ganglion cell complex volume is defined as either borderline (seen in p < 5 per cent of the general population) or abnormal loss (seen in p < 1 per cent of the general population) in comparison to an age-matched normative database. Twenty-five per cent of individuals with diabetes and DPN, 11 per cent of those with diabetes with no DPN, and five per cent of non-diabetic controls had abnormal focal loss volume. The proportion of the nondiabetic controls with this loss (five per cent) was within acceptable limits of normality (p ≥ 5 per cent), when compared to 25 and 11 per cent in the diabetic group. Factors associated with this abnormal focal loss in ganglion cell complex volume were analysed in diabetic individuals. This loss was found to be associated with DPN, irrespective of age, sex, and diabetic retinopathy, duration of the disease, HbA 1c levels and the type of diabetes. Interestingly, the ganglion cell complex thickness was observed to be relatively normal.
These above findings have been reconfirmed by Salvi et al. 90 and Hegazy et al. 91 Salvi et al. 90 investigated the average retinal nerve fibre layer and ganglion cell complex thicknesses, focal and global loss volumes in individuals with diabetes, specifically in relation to diabetic retinopathy and neuropathy.
None of the aforementioned parameters showed significant differences between 'no retinopathy', and other stages of retinopathy. Comparison between those with and without neuropathy showed significantly different focal loss volumes, in the presence of a relatively normal nerve fibre layer and ganglion cell complex thicknesses and global loss volume. These findings suggest the possibility that the ganglion cell loss may start as focal losses which may progress further to manifest as a thinner ganglion cell complex layer. One way to examine this proposition is to compare inner retinal parameters with respect to severity of neuropathy. If this proposition were true, one would expect ganglion cell complex thickness to be lower with increasing severity of neuropathy. Hegazy et al. 91 examined individuals with diabetes without retinopathy and those with no diabetes. Focal loss volume was significantly higher in those with diabetes but no retinopathy, compared to those with no diabetes, raising the possibility of early neuronal degeneration unrelated to diabetic retinopathy. Kim et al. 92 assessed overall retinal thickness, and individual layer thicknesses and ganglion cell-inner plexiform layer thickness, in relation to nerve conduction velocities in the peroneal, sural and tibial nerves in the leg, as well as in relation to autonomic neuropathy measures. The authors observed that ganglion cell-inner plexiform layer thickness was correlated with nerve conduction parameters and autonomic neuropathy measures; however, there was no significant correlation with retinal thickness. The above studies support the notion that changes in the inner retinal measures can be detected earlier than changes in full retinal thickness in relation to peripheral neuropathy measures, in the presence of mild or no diabetic retinopathy. This suggests that both diabetic complications may coexist and that retinal neuronal degeneration in diabetes may start at the inner retinal layers in relation to peripheral neuropathy rather than with retinopathy.
We also found that abnormal global loss in ganglion cell complex volume was not significantly different between groups with and without DPN and non-diabetic controls; specifically, 14 per cent in those with DPN, 10 per cent in those with diabetes but no DPN, and two per cent in the non-diabetic control group, had abnormal global loss in ganglion cell complex volume, although the differences were not statistically significant. The proportion of individuals with this abnormality was within the acceptable range for the non-diabetic control group, but was still abnormal in the diabetic group. Further analysis conducted only in the diabetic group revealed that an abnormal global loss in ganglion cell complex volume in diabetes is associated with increasing age, but not with diabetic retinopathy, DPN, sex, disease duration, or HbA 1c levels. 88 Results from the above studies confirm that ganglion cells are lost early in diabetes irrespective of the presence or the stage of diabetic retinopathy. This may suggest that there are focal/local losses in the ganglion cell complex in the presence of an essentially normal thickness of the ganglion cell complex. This could also mean that ganglion cell complex loss starts as a focal loss, which subsequently becomes widespread, eventually manifesting as a reduction in ganglion cell complex thickness.
Given that OCT-derived parameters are associated with DPN, we examined the diagnostic capability of OCT-derived parametersnamely, retinal thickness measures at the macula, nerve fibre layer thickness and ganglion cell complex thickness, and its patternbased volume parameters 93 ( Figure 3 95 observed that retinal nerve fibre layer thickness and ganglion cell-inner plexiform layer thicknesses are independently associated with cardiac autonomic function, assessed by heart rate variability (with deep breathing and a change in posture from lying to standing position). Total macular and inner retinal layer volumes have also been reported to be associated with heart rate variability (a measure of autonomic neuropathy) in individuals with diabetes. 96 Neriyanuri et al. 97 assessed retinal function by means of colour vision, contrast sensitivity testing and microperimetry. These retinal functional measures were reported to be compromised in patients with DPN in the absence of diabetic retinopathy (assessed by vibration perception threshold in the distal leg) compared to those without DPN. Reduced retinal sensitivity assessed by microperimeter has been shown to be independently associated with DPN. 97 To date, the utility of OCT has been established for detecting neuroretinal degeneration, primarily in the context of cross-sectional studies. However, in our longitudinal study, 98 retinal nerve fibre layer thickness was found to progressively decrease in those with DPN. The rate of thinning of the overall retinal nerve fibre layer was reported to be 0.7 μm per year, and about 1.9 μm per year in the superior quadrant. This reduction in thickness was found to be unrelated to sex, retinopathy, diabetes duration, HbA 1c , lipid profile, blood pressure, cigarette use, alcohol consumption or body mass index. We have also investigated the capability of OCT to predict four-year incident DPN. 99 The baseline measures of mean parafoveal thickness (inner macula) were significantly lower in those who developed DPN after four years compared with those who did not develop DPN. When adjusted for age, retinal thickness in the parafoveal zone demonstrated 86 per cent sensitivity and 44 per cent specificity for a criterion of 321 μm, in addition to body mass index, which had 49 per cent sensitivity and 83 per cent specificity at a criterion of 29.3 kg/m 2 . The areas under the receiver operating characteristic curves and the 95 per cent confidence intervals for the parafovea were 0.977 (0.957-0.997). However, at this stage, we believe that OCT does show some promise in identifying individuals who may be at risk of developing DPN in the future. All studies related to OCT in diabetic neuropathy are summarised in Figure 4 .
The pathogenesis behind neuronal compromise in diabetes has been hypothesised as being related to an alteration of the blood-retinal barrier and inflammatory processes. 100 Hyperglycaemia-induced oxidative stress and accumulation of advanced glycation end products have been proposed as pathological mechanisms underpinning neuroretinal and glial tissue apoptosis. 98 These mechanisms in neuropathy are not restricted to the peripheral nervous system, but also affect components of the central nervous system, indicating that diabetesrelated pathology influences multiple neural network systems. Full retinal tissue thickness, macular and peripapillary nerve fibre layer thickness are compromised in individuals with DPN. These findings have important implications for visual function, especially central vision, colour vision and visual fields. Also, those with neuropathy often have compromised mobility, which could lead to falls and further jeopardise their quality of life. Eye care practitioners must note that the absence of diabetic retinopathy does not rule out any retinal complications. Individuals can have associated neuroretinal complications which may be associated with undiagnosed DPN.
Due to the transparent nature of the retinal nerve fibre layer, a compromise to the neural layers may or may not be noticeable during a routine eye examination. Therefore, these individuals need to be referred to their health care provider for appropriate follow-up so as to detect undiagnosed disease or other micro-or macro-vascular complications of diabetes. This would help in intervening at the early stages so that any avoidable complications can be prevented.
Conversely, once these retinal findings have been established as markers, ophthalmic screening may detect a previously undiagnosed neuropathy. Patients can be subsequently referred to a specialist for a comprehensive evaluation. Endocrinologists can play a significant role in working with patients to achieve optimal glycaemic levels, as well as in counselling the patient in glucose self-monitoring. Podiatrists can assist by educating patients about the importance of regular health check-ups and proper foot care. Counselling and advice regarding proper fitting shoes and protection of sensitive areas in the feet should be emphasised. eventually established as 'markers' and validated, then eye care practitioners may assume an important role as part of multidisciplinary teams that include diabetic physicians, neurologists and podiatrists, in identifying and monitoring patients with neurological problems. A timely referral and management plan can prevent or delay unnecessary consequences. Ongoing refinement of the OCT technique is likely to further our understanding of the already impressive capabilities of this tool for investigating and diagnosing neurologic disease.
